Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
Studies from H.K. Valian and colleagues yield new information about leishmaniasis
August 13th, 2008
According to a study from Iran, "Various Leishmania antigens showed to induce protection when used with IL-12 as an adjuvant in an animal model of leishmaniasis. Limitations in using IL-12 justify searching for an appropriate adjuvant to accelerate induction of a Th1-type immune response and protection." "In this study, the role of Mycobacterium vaccae as an adjuvant mixed with either autoclaved Leishmania major (ALM) or freeze-thawed-killed L. major (KLM) in increasing protection in susceptible and resistant mice was studied. Nineteen groups of BALB/c and 19 groups of C57BL/6 mice, ten mice per group, were immunized three times in 45 days interval with different doses...
Source: Vaccine Weekly (2008-08-13)
|
